Campbell & CO Investment Adviser LLC Acquires Shares of 30,418 Stoke Therapeutics, Inc. $STOK

Campbell & CO Investment Adviser LLC bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,418 shares of the company’s stock, valued at approximately $715,000. Campbell & CO Investment Adviser LLC owned about 0.06% of Stoke Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets grew its stake in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in shares of Stoke Therapeutics by 33.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after acquiring an additional 2,384 shares in the last quarter. Finally, KLP Kapitalforvaltning AS increased its holdings in shares of Stoke Therapeutics by 131.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $150,000 after acquiring an additional 7,500 shares during the last quarter.

Insiders Place Their Bets

In related news, Director Adrian R. Krainer sold 40,472 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the transaction, the director owned 364,246 shares in the company, valued at $9,827,357.08. This represents a 10.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Barry Ticho sold 5,931 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $25.72, for a total transaction of $152,545.32. Following the transaction, the insider directly owned 7,195 shares in the company, valued at approximately $185,055.40. The trade was a 45.19% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 104,705 shares of company stock worth $3,070,910. 9.50% of the stock is owned by company insiders.

Stoke Therapeutics Trading Up 0.1%

STOK opened at $28.72 on Wednesday. The business’s 50 day moving average is $30.96 and its 200-day moving average is $24.70. The stock has a market cap of $1.64 billion, a PE ratio of 42.87 and a beta of 1.10. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on STOK shares. Canaccord Genuity Group raised their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research report on Monday, January 5th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. HC Wainwright increased their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Wedbush lifted their target price on Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.10.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.